2026-02-24
Polyphenol Stack Synergy: Quercetin, Resveratrol, Curcumin, and EGCG Combined Evidence
Quercetin, resveratrol, curcumin, and EGCG activate overlapping pathways — NRF2, SIRT1, AMPK, and NFkB inhibition. Stacking them is popular but evidence for synergistic human benefit is largely extrapolated from in vitro and animal models. This article assesses what stacking adds and what it does not.
2026-02-19
Polyphenol Protocols in Cognition Clinics: Clinical Context and Evidence Limits
Resveratrol, quercetin, and fisetin are used in some cognition-focused protocols, but human evidence is mixed and best interpreted as adjunctive support rather than primary therapy.
2026-02-17
Caloric Restriction Mimetics in 2025: Multi-Pathway Geroprotectors Under Clinical Evaluation
A 2025 Biogerontology review maps geroprotective compounds targeting AMPK, mTOR, and autophagy pathways. Most remain at biomarker endpoints; hard longevity data in humans is largely absent.
2026-01-21
Visceral Fat Reduction: Berberine, GLP-1 Context, Diet, and Exercise — Evidence Review
Visceral adipose tissue is metabolically active and a major driver of chronic disease. Caloric deficit and exercise are primary — supplements like berberine and chromium provide meaningful but adjunctive support. GLP-1 context is relevant for clinical framing.
2026-01-11
Green Tea EGCG: Metabolic Effects, Longevity Pathways, and Bioavailability
EGCG (epigallocatechin gallate) is green tea's primary bioactive catechin. Evidence supports modest effects on body composition, insulin sensitivity, and cardiovascular markers, though bioavailability from supplements varies significantly.